1. Home
  2. OPP vs PBYI Comparison

OPP vs PBYI Comparison

Compare OPP & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OPP
  • PBYI
  • Stock Information
  • Founded
  • OPP 2010
  • PBYI 2010
  • Country
  • OPP United States
  • PBYI United States
  • Employees
  • OPP N/A
  • PBYI N/A
  • Industry
  • OPP Finance/Investors Services
  • PBYI Biotechnology: Pharmaceutical Preparations
  • Sector
  • OPP Finance
  • PBYI Health Care
  • Exchange
  • OPP Nasdaq
  • PBYI Nasdaq
  • Market Cap
  • OPP 199.8M
  • PBYI 167.3M
  • IPO Year
  • OPP N/A
  • PBYI N/A
  • Fundamental
  • Price
  • OPP $8.39
  • PBYI $3.31
  • Analyst Decision
  • OPP
  • PBYI Strong Buy
  • Analyst Count
  • OPP 0
  • PBYI 1
  • Target Price
  • OPP N/A
  • PBYI $7.00
  • AVG Volume (30 Days)
  • OPP 108.0K
  • PBYI 354.2K
  • Earning Date
  • OPP 01-01-0001
  • PBYI 07-31-2025
  • Dividend Yield
  • OPP 14.41%
  • PBYI N/A
  • EPS Growth
  • OPP N/A
  • PBYI 143.51
  • EPS
  • OPP N/A
  • PBYI 0.77
  • Revenue
  • OPP N/A
  • PBYI $232,709,000.00
  • Revenue This Year
  • OPP N/A
  • PBYI N/A
  • Revenue Next Year
  • OPP N/A
  • PBYI N/A
  • P/E Ratio
  • OPP N/A
  • PBYI $4.34
  • Revenue Growth
  • OPP N/A
  • PBYI 2.68
  • 52 Week Low
  • OPP $7.26
  • PBYI $2.23
  • 52 Week High
  • OPP $8.83
  • PBYI $4.13
  • Technical
  • Relative Strength Index (RSI)
  • OPP 49.88
  • PBYI 47.57
  • Support Level
  • OPP $8.32
  • PBYI $3.34
  • Resistance Level
  • OPP $8.41
  • PBYI $3.39
  • Average True Range (ATR)
  • OPP 0.06
  • PBYI 0.16
  • MACD
  • OPP -0.00
  • PBYI -0.04
  • Stochastic Oscillator
  • OPP 48.76
  • PBYI 19.05

About OPP RiverNorth/DoubleLine Strategic Opportunity Fund Inc.

RiverNorth/DoubleLine Strategic Opportunity Fund Inc is a closed-end management investment company. The company's investment objective is to seek current income and overall total return.

About PBYI Puma Biotechnology Inc

Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.

Share on Social Networks: